Mission

We are a full service, global pharmaceutical CRO lab that provides high quality service to our clients and provides opportunities for our employees in grow a career in a healthy work environment.

Vision

To become one of the best CROs in the world by providing the best service possible, using the best technical know-how at a reasonable value, to enable our clients to develop life-saving medications.

Values

Quality We are committed to excellence in the results we achieve, and how we achieve them.

Integrity Being honest, reliable and accountable in our words and behavior, doing the right things for our clients, company, community, and ourselves.

Respect for people. Promote a diverse culture and commitment to mutually respect our teammates, our customers, and people around us.

Collaboration Working together to achieve common goals is the foundation of our success; seek input and listen, and be flexible and responsive.

Song Li, Ph.D.

Song Li, Ph.D.

Chairman, Frontage Holdings
Song Li, Ph.D.

Song Li, Ph.D.

Chairman, Frontage Holdings

Dr. Song Li founded Frontage Laboratories in 2001 with the ambition of building a client-focused organization to help solve the most complex drug development challenges. Prior to Frontage, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During this time, he led numerous projects related to the development of pharmaceutical products.

Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Importantly, Dr. Li has been the recipient of numerous awards, most recently Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, Ernst & Young Entrepreneur of the Year Award,  the “Realizing the American Dream” award from the Pennsylvania Welcoming Society, and the Outstanding 50 Asian Americans in Business Award from the AABDC.

Dr. Li earned a doctor of philosophy degree in analytical chemistry from McGill University and a bachelor of science degree in chemistry from Zhengzhou University in China.

 

linkedin logo 150x150 - Song Li, Ph.D.

 

Read Full Bio
Henry Gao

Henry Gao

CFO, APAC President
Henry Gao

Henry Gao

CFO, APAC President

Mr. Henry Gao is Frontage Laboratories’ President of Asia Pacific operations. Henry is an accomplished professional with over 25 years of experience in privately held and publicly listed global organizations leading functions including finance, audit, investment, project management, general management, IPO, and M&As.

From 2018 to 2022 Henry was a member of the board of directors of Frontage Holdings Corporation. Henry’s board level and executive leadership has been well recognized in the CRO and the biotech industries in the APAC region and beyond.

Prior to this appointment, since September 2021, Henry was the executive director and CFO of Shanghai Duoning Biotechnology Co., Ltd. From November 2016 to September 2021, he was the board secretary, deputy general manager and CFO at Hangzhou Tigermed Consulting Co., Ltd. Prior to that and until October 2016, he has held the CFO and board secretary role at Shanghai Xiaoi Robot Technology Corporation Limited. From May 2011 to December 2015, he was the chief financial officer and board secretary of McWong Environmental Technology Corporation Limited.

Before that, Henry has held various positions in Hong Kong Shanghai Alliance Holdings Limited, City North Infrastructure Pty Ltd., Rio Tinto Group, and Felix Resources Ltd. From May 2001 to June 2007, he worked at Foster Wheeler AG in a variety of leadership roles including the China finance manager, chief compliance officer and project control director for Asia. He began his career with PWC Business Consulting in Shanghai, China.

Henry received his bachelor’s degree from Shanghai University of Finance & Economics, China, majoring in international accounting. He is a Certified Public Accountant in China, an internationally accredited Certified Internal Auditor, an Associate of the Chartered Institute of Management Accountants (UK), a member of the Association of International Certified Professional Accountants (US & UK) and a Fellow of the Association of Chartered Certified Accountants (UK).

Read Full Bio
Chengwei Fang

Chengwei Fang

SVP of Frontage China, Strategic customer business expansion
Chengwei Fang

Chengwei Fang

SVP of Frontage China, Strategic customer business expansion

Dr. Fang has over 20 years of experience in pharmaceutical and agrochemical R&D. Before joining Frontage, he worked as an Environmental Fate and Metabolism Researcher at BASF Agro Research (2000-2004). He then moved on and joined Merck Company (2004-2006) and AstraZeneca Pharmaceuticals LP (2006-2010) and engaged in both discovery and regulated bioanalysis research. He served as Executive Director, Head of DMPK and Regulated Bioanalysis Department at Pharmaron (2010-2014), and as Principal Investigator of Environmental Fate and Metabolism at Corteva Agriscience (2014-2020).

Dr. Fang has rich experience in the areas of ADME, PK/TK, and bioanalysis to support pharmaceutical R&D, environmental fate and metabolism of pesticides and regulatory sciences to support agrochemical registration.  He has extensive knowledge on GXP regulations from various authorities including FDA, NMPA, OECD and EPA. He has proven strengths in managing multiple projects and performing complex analytical tasks and has excellent track record on leading teams and delivering high-quality services to clients. Dr. Fang graduated from Delaware University in 1999 with a Ph.D. in Plant and Soil Science.

Read Full Bio
Alicia Du

Alicia Du

SVP of Frontage China, Safety/Tox & DMPK
Alicia Du

Alicia Du

SVP of Frontage China, Safety/Tox & DMPK

Dr. Du has over 15 years of US industry experience in drug discovery and development, with a particular focus on biometabolism and bioanalytical (including GLP compliant, GCP clinical sample analysis). She has led and fully participated in two drug candidates for IND filings in the bioanalytical and DMPK areas, including the successful IND and NDA submissions for Sustiva (HIV drug), and the IND and clinical phase I and II DMPK studies for Pfizer’s anti-cancer drug Sutent-Sotan, and has deep expertise in mass spectrometry. Prior to joining Frontage, Dr. Du was the founder and CSO of Calibra, a technology company focused on clinical testing and clinical biomarker development and IVD kit manufacturing.
Dr. Du graduated from Brigham Young University, Provo, Utah, with a Ph.D in analytical chemistry (1991-1996). She has a patent (Alicia (Yinghua) Du, “Method of Neonatal Urine Screening for Organic Acid” U.S. Patent, US2010/ 0126254A1, May 27, 2010). 0126254A1, May 27, 2010, Mass Spectrometry of Organic Acids in Neonatal Urine) and more than 50 abstracts from journals and academic conferences. Contributed several chapters in two books on drug analysis and toxicology. He has taught several short courses on bioanalysis, especially at the China Mass Spectrometry Conference and at the ASMS Mass Spectrometry User Conference in the US. Dr. Du is one of the founding members of CBF (China Bioanalytical Forum) and has led and participated in the successful annual meetings in Beijing, Shanghai and Nanjing for several years.

Read Full Bio
Mankit

Mankit

SVP of Frontage China, CMC China General Manager
Mankit

Mankit

SVP of Frontage China, CMC China General Manager

Dr. Mankit Ho leads the Frontage CMC (Chemistry Manufacture & Control) Services in China, which include products development, analytical services, and manufacturing of clinical trial materials. Dr. Ho has more than 20 years pharmaceutical experience in pharmaceutical products development. Prior to joining Frontage, Dr. Ho held senior positions at Kashiv Pharma (Senior Vice President) and Teva Pharmaceuticals/Barr Laboratories (Director), where he led teams in successfully developed, filed, and approved for numerous generic (ANDA), 505(b)(2), new drug (NDA) products.

Dr. Ho earned a PhD degree in Analytical Chemistry from Iowa State University, followed by postdoctoral research at The University of Arizona. He received a BS degree in Chemistry from The Chinese University of HongKong.

Read Full Bio
Yaodong Huang

Yaodong Huang

SVP of Frontage China Medicinal chemistry
Yaodong Huang

Yaodong Huang

SVP of Frontage China Medicinal chemistry

PhD (UCSB)；Acme（8 years)； SYNthesis Med Chem (VP of Chemistry)； Haoyuan Chemexpress (Executive VP of Chemistry）Joined Acme in 2023

Read Full Bio
Min Wang

Min Wang

VP of Frontage China，BE&Early Clinical
Min Wang

Min Wang

VP of Frontage China，BE&Early Clinical

Min Wang has more than 10years of industrial experience. Before joined in Frontage, She had been worked as project director and team leader for project managers. The therapeutic areas she had been involved including oncology, endocrinology, cardiology, gastroenterology, rheumatology and immunology studies from phase I till phase III, as well as in Vitro Diagnostic trials. She has chaired many studies passed inspection by CFDI, before the product marked.

Min Wang graduated from North China Coal Medical University, and now is working towards master’s degree of EMBA. Min had been working in Southerncross healthcare group as assistant Nurse in England from 2008 till 2010.

Read Full Bio
Lian Chen

Lian Chen

VP of Frontage China Biological Analysis
Lian Chen

Lian Chen

VP of Frontage China Biological Analysis

Dr. Chen has been engaged in bioanalysis and DMPK research in the United States for more than 10 years, and has enriched  CRO experience of  laboratory operation, scientific management and business development, and is an expert in GLP related regulations. She has rich experience in the development and validation of small molecules, metabolites, preparation samples, biomarkers, peptides, antibody conjugated drugs and oligonucleotides by LC-MS. Dr. Chen has published more than 10 papers and reports in famous foreign journals.

Dr. Chen earned PhD degree in college of pharmacy from University of Illinois, received Bachelor degree in medicine from Wuhan University.

Read Full Bio
Yuwen Chen

Yuwen Chen

VP & TFM of Safety and Tox Center, Frontage China
Yuwen Chen

Yuwen Chen

VP & TFM of Safety and Tox Center, Frontage China

Dr. Chen has nearly 10 years experiences in toxicology studies of drug R&D. She is proficient in basic science and translational medicine, familiar with GLP regulations of many countries, animal welfare regulations and toxicological evaluation guidelines. She is trusted and recognized by customers in project management and preclinical trial analysis and design. Dr. Chen has got DABT certificate.

Read Full Bio
Liu Shi

Liu Shi

VP of Frontage China, Biology & Pharmacology
Liu Shi

Liu Shi

VP of Frontage China, Biology & Pharmacology

Mrs. Shi has accumulated rich experience in the early stage of drug development activity screening, focusing on the development and validation of various in vitro screening systems related to drug development targets such as GPCR, nuclear receptor, enzymology and high throughput screening.

Mrs. Shi graduated from Beijing Institute of genome research, Chinese Academy of Sciences.

Read Full Bio
June Xiao

June Xiao

Vice President of China QA
June Xiao

June Xiao

Vice President of China QA

Has in depth knowledge of quality&compliance in research and development and manufacturing process in the pharmaceutical healthcare industry.
She began her professional career as analytical chemist in the GMP manufacturing facilities of Wyeth and Organon in Ireland for over 12 years,assumed various positions in the quality control,technical validation departments with increasing responsibility as team leader and section leader.
She moved back to China in early 2006,joined Frontage in Shanghai during its starting phase as QA director, and later on move to V.P. position responsible for overall quality system in the China operation.
In early 2010,she joined Johnson&Johnson global pharma R&D QA organization as QA director supporting all global and regional non regulated,preclinical and GCLP projects in the region.

Read Full Bio
Chenxi Wang

Chenxi Wang

VP of Frontage China, Business Development
Chenxi Wang

Chenxi Wang

VP of Frontage China, Business Development

Mr. Chenxi Wang has enriched experience in biopharmaceutical field for many years, and has a deep client base in clinical and laboratory business for both novel and generic drugs at home and abroad. He has accumulated extensive experience in sales strategy development, business negotiation, business development and maintenance. Mr. Chenxi Wang worked for Frontage China from 2015 to 2020, and then was responsible for business development and management in PPD, Huapu Pharma, WuXi Clinical etc.

Chenxi Wang earned his master degree in basic veterinary medicine from Huazhong University in 2014.

 

Read Full Bio
en_USEnglish
zh_CNChinese en_USEnglish